CAR T-Cell Therapy: Adverse Events and Management

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Chimeric antigen receptor (CAR) T-cell therapy represents a significant advancement in cancer treatment.
• This therapy is associated with unique adverse events (AEs), including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• Other observed AEs include cytopenias and infections, which are manageable but require prompt attention.

Purpose of the Study:

• To provide updated recommendations for grading and managing adverse events associated with CAR T-cell therapy.
• To ensure advanced practitioners have a thorough understanding of CAR T-cell-related toxicities.
• To facilitate broader access to CAR T-cell therapy by minimizing severe, life-threatening AEs.

Main Methods:

• Review and synthesis of recent clinical trial data and expert consensus on CAR T-cell therapy adverse events.
• Development of standardized grading criteria for CRS and ICANS.
• Outline of evidence-based management strategies for various grades of AEs.

Main Results:

• Established consistent grading and management guidelines for CAR T-cell therapy-associated AEs, addressing CRS and ICANS specifically.
• Highlighted the spectrum of severity for CRS and ICANS, from low-grade manageable symptoms to life-threatening conditions.
• Emphasized the treatable and reversible nature of these AEs with appropriate interventions.

Conclusions:

• Adherence to updated grading and management guidelines is essential for optimizing patient outcomes in CAR T-cell therapy.
• Effective management of AEs can mitigate risks, allowing patients to benefit from this potentially curative cancer treatment.
• Standardized approaches to AE management will improve safety and accessibility of CAR T-cell therapy.